Elutia has reached a definitive agreement to sell its EluPro and CanGaroo bioenvelopes to Boston Scientific for $88m in cash. This transaction is stated to allow Elutia to advance its development and commercialisation efforts of its near-term pipeline without diluting shareholder value. The EluPro BioEnvelope comprises a “unique” extracellular matrix designed to facilitate the regeneration of healthy, vascularised tissue while preventing post-operative complications. The bioenvelope is designed to relea ...